Adjuvant Low Dose Aspirin in Colorectal Cancer

ABSTRACT: ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2205561 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR